𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

✍ Scribed by Hagop M. Kantarjian; Richard A. Larson; Francois Guilhot; Stephen G. O'Brien; Manisha Mone; Marc Rudoltz; Tillmann Krahnke; Jorge Cortes; Brian J. Druker

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
59 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Dynamics and management of cytopenias as
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
✍ Alfonso QuintΓ‘s-Cardama; Fabio Pires De Souza Santos; Hagop Kantarjian; Susan O' πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 160 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. ## METHODS: Data were analyzed from 130 patients with CP CML who were trea

Phase 1 study of tipifarnib in combinati
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
✍ Jorge Cortes; Alfonso QuintΓ‘s-Cardama; Guillermo Garcia-Manero; Susan O'Brien; D πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 92 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The tolerability and efficacy of the combination of tipifarnib, an orally bioavailable nonpeptidomimetic farnesyl transferase inhibitor, and imatinib was investigated in patients with chronic myelogenous leukemia in chronic phase who had failed imatinib. ## METHODS. Tw

Cost-effectiveness of imatinib versus in
Cost-effectiveness of imatinib versus interferon-Ξ± plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia
✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 119 KB

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment